Instant Removal of Non-Value Add for Pharmaceutical Industries

In: Business and Management

Submitted By woolange
Words 424
Pages 2
A Good Point
Half Day Executive Briefing: Lean Pharma Series

Pada tanggal 16 Februari lalu, SSCX menyelenggarakan mini-briefing yang bertajuk “Instant Removal of Non-Value Add for Pharmaceutical Industries” sebagai bagian dari Lean Pharma Series. Acara yang dihadiri oleh plant dan production manager dari perusahaan-perusahaan farmasi terkemuka di Indonesia ini bertujuan untuk memunculkan urgensi untuk menghilangkan waste yang kerap terjadi dalam operasional pabrik obat dan produk kesehatan, dan meningkatkan efisiensi proses. Tujuan akhirnya adalah Operational Excellence, sustainability dan profitability.
Pada seminar yang diselenggarakan di Harris Hotel Sentul ini, konsultan senior SSCX, Riyantono, membuka pembicaraan dengan menjelaskan tentang beberapa tantangan yang muncul di industri farmasi, seperti kerugian yang terjadi akibat pergantian mesin dan pembersihan mesin, kerugian yang terjadi akibat cacat produk dan pengerjaan ulang, kerugian akibat kerusakan mesin dan penurunan kecepatan kerja (idle/loss speed time), proses leadtime yang panjang, penumpukan inventori, serta biaya operasional yang tidak kompetitif. Sebagai bagian dari program eliminasi waste, dijabarkan pula mengenai value dan waste, termasuk 7 waste (inventory, motion, waiting time, defective products, transportation, overprocess, overproduction) yang merupakan non-value added activity.
Riyantono menjelaskan mengenai Lean, yang merupakan metode solusi dalam menghilangkan kerugian-kerugian (waste) yang kerap terjadi di industri farmasi. Beberapa tool Lean yang disajikan antara lain Value Stream Map (VSM), yang berfungsi meningkatkan kegunaan dari proses mapping dengan menambahkan data seperti material, arus informasi, parameter operasional, leadtime, dan sebagainya.
Selama seminar berlangsung, dijelaskan pula langkah-langkah dalam menggunakan tool VSM tersebut. Langkah awal membuat VSM…...

Similar Documents

An Overview of the Uk Pharmaceutical Industry

...An Overview of the UK Pharmaceutical Industry The Pharmaceutical Industry in the UK is the second largest contributor to Gross Domestic Product behind Financial Services. There are several very big players in the UK with GlaxoWelcome & SmithKline Beecham who merged in January 2000 to become Glaxo SmithKline and AstraZeneca being the two largest UK based companies. Almost all the other major pharmaceutical companies operating in the UK have undergone or are in the process of undergoing mergers and acquisitions, including AstraZeneca, Pfizer and Warner Lambert, Shire and Roberts, and Celltech with Chiroscience and Medeva. The UK pharmaceutical market is a successful, research-driven, high-technology industry. The UK market is dynamic and increasingly competitive and, it ranks third after Germany and Switzerland in the global pharmaceutical industry rankings in terms of trade balance. According to the Association of the British Pharmaceutical Industry (Abpi), the industry employs around 75,000 people, of whom over 25% are graduates. Introduction to AstraZeneca AstraZeneca is one of the world’s leading pharmaceutical companies, with a major presence in the UK. Their business is focused on providing innovative, effective medicines that make a real difference in important areas of healthcare. Other facilities in the UK include research and development, sales and marketing and manufacturing. In 2008 AstraZeneca’s total contribution to wealth creation was £4.1 billion...

Words: 1059 - Pages: 5

Pestel Analysis of Pharmaceutical Industry

...A SWOT analysis identifies and assesses the strengths, weaknesses, opportunities and threats an organization faces. A SWOT analysis of the pharmaceutical industry illustrates to upper management what the industry is excelling in, what improvements need to be made, where growth is possible and what preemptive measures need to be taken to protect shareholder or company value. Strengths • The strengths of the pharmaceutical industry’s SWOT analysis document the internal industry components that are providing value, quality goods and services and overall excellence. The internal industry components can include physical resources, human capital or features the industry can control. For example, the pharmaceutical industry’s strengths could include low operating overhead, firm fiscal management, low staff turnover, high return on investment (ROI), state-of-the-art laboratory equipment and an experienced research staff. Weaknesses • The weaknesses of the pharmaceutical industry’s SWOT analysis document the internal industry components that are not providing significant added value or are in need of improvement. The internal industry components can include physical resources, human capital or features the industry can control. For example, the pharmaceutical industry’s weaknesses could include high-risk business modeling, disengaged Board of Directors, dated medical equipment, poor branding, low staff morale or diseconomies of scale. • Sponsored Links o viral clearance......

Words: 393 - Pages: 2

Teva Pharmaceutical Industries, Ltd

...9-707-441 REV: MARCH 30, 2010 TARUN KHANNA KRISHNA PALEPU CLAUDINE MADRAS Teva Pharmaceutical Industries, Ltd In Israel we have a 1970s song based on a poem from 1953 by Amir Gilboa about Theodor Herzl.1 It has a line in it about Herzl: “Suddenly a man rises in the morning, feels he is a people, and starts walking.” That is exactly what Hurvitz did. Suddenly he woke up in the morning, feels he is a giant world class company, and starts walking. No one, aside from Herzl, has accomplished anything as remotely as impressive in this country as Hurvitz. It was impossible, a million to one odds at best, and he still did it. He woke up one morning and started walking. — Ori Hershkovitz, equity analyst at Tel Aviv-based Leader & Company The markets had not been kind to Teva Pharmaceutical during the first half of 2006. The stock had plunged nearly 30% from January 1 to June 30, erasing billions of dollars from the company’s market capitalization. Even good news, such as reports in July of Teva’s wildly successful introduction of generic Zocor—the largest blockbuster drug ever to go off-patent—had failed to boost the stock significantly. Since nearly every retirement fund and mutual fund in Israel invested in Teva, this drop had been felt throughout the population, in effect amounting to every Israeli family losing NIS 3000, or $675.1 Teva was more than the world’s leading producer of generic pharmaceuticals (see Exhibit 1 for financials). It represented the gold standard of......

Words: 12524 - Pages: 51

Economics of the Pharmaceutical Industry

...------------------------------------------------- Economics of the Pharmaceutical Industry Some of the factors affecting Supply in the Pharmaceutical Industry September 18, 2013 MBA BATcH 8 Prepared by: Amel Mohamed, Muna Abbas & Wafaa Gaafer September 18, 2013 MBA BATcH 8 Prepared by: Amel Mohamed, Muna Abbas & Wafaa Gaafer The well-being of the pharmaceutical industry is dependent largely on the economy. It is also a heavily regulated industry. Drugs are evaluated for safety, efficiency, and manufacturing quality as a condition of market access, and promotional messages must adhere to approved product characteristics. Drug prices also are regulated in most countries with national health insurance systems. The main factor that affects the industry is employment because a majority of Sudanese receive health insurance through their employers. Other economic factors such as the number of people who are uninsured or underinsured, performance and industry structure, the effects of regulation on prices, availability and utilization of drugs and productivity as well as the government stimulus plans also affects the industry. Unemployment Paramount to any industry is the number of people who are unemployed. In the first decade of the 20th century, this became a major political issue in the United States. Unemployment affects the pharmaceutical industry in two major ways. First, people who do not have jobs usually do not have the funds to buy the......

Words: 683 - Pages: 3

Sales Forece Effectiveness in the Pharmaceutical Industry

...Sales Force Effectiveness in the Pharmaceutical Industry Edward C. Twyford August 25, 2013 MBA 525 Professional Development Abstract With the advent of healthcare reform, increased government regulation and market saturation the pharmaceutical industry has been faced with a multitude of challenges. Scrutiny as to over cost of pharmaceutical sales organization has gained popularity with senior pharmaceutical executives as well as Wall Street Analysts. Both parties attempted to put a price tag on the sales organization in comparison to direct sales. Faced with no comprehensive data based tool for this evaluation, most evaluations where left to speculation and subjective conclusions. In 2008 Andris A. Zoltners, Ph.D. and Sally E. Lorimer, M.M. both from the Kellogg School of Management at Carnegie Mellon University collaborated with Prabhakant Sinha, Ph.D. from the University of Massachusetts to publish the foundation of Sales Force Effectiveness Framework. This framework applied to pharmaceutical sales organizations worldwide defined the study of effectiveness in these organizations. We will define Sales Force Effectiveness Framework and look at the methodology used to arrive at this template. We will then explain the drivers, the key components, of SFEF and look at examples of SFEF incorporated in sales force evaluation. Through these examples one the ability for companies to use cross functional teams to better and more efficiently solve problems is evident. Another......

Words: 2534 - Pages: 11

Indian Pharmaceutical Industry

...Indian Pharmaceutical Industry The Indian pharmaceutical industry has seen tremendous growth in the last decades and is one of the fastest growing pharmaceutical markets in the world. It is the fourth largest pharmaceutical market in the Asia Pacific region behind Japan, China and South Korea. However, the per capita spending of US$12 is among the lowest in the world, similar to levels in Pakistan and Vietnam. .India accounts for almost 10% of the global market by volume and is rapidly emerging as the leading outsourcing partner of global pharmaceutical companies, strengthened by improving Research and Development (R&D) focus and strategic position in the pharmaceutical value chain. The Industry structure of Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units with severe price competition and government price control. There are about 3,000 pharmaceutical manufacturers, the vast majority of which focus on generic drugs. The major players in the industry are Ranbaxy, Cipla, Dr. Reddy's Laboratories, Lupin, Nicolas Piramal,Aurobindo Pharma, Cadila Pharmaceuticals, Sun Pharma, W Wockhardt Ltd. and Aventis Pharma. The industry encourages international interest because of the growing population and economic improvements . Furthermore, initiatives of the Government such as allowing 100% FDI under the automatic route in drugs and pharmaceuticals including those involving use of recombinant technology act as a catalyst for......

Words: 257 - Pages: 2

The Global Pharmaceutical Industry

...Q1. Identify the main environment forces currently affecting the pharmaceutical industry. PESTLE analysis is used to help the organization to understand what is the current status of the organization and the external factors that are affecting it, whereas this also helps the management of the organizations to overcome the weak areas organizations by implementing the strategy for the future. Political The policies of the government had a great effect on the regulations and legal issues that defines both formal and informal rules for the industries innovations as compared to the other factors in the form of “parallel trade” as the attention of the industry was an increase in the economic importance’s where the government offered incentives that encouraged the industry to globalization as they focused on pharmaceutical industry to handle the challenges of price control, monopoly and trade. Overtime this led to a wide disparity in prices that exposed the industry to sensationalist newspaper headlines and consumer backlash. Economic The sales in the pharmaceutical related closer to the GDP due to the effect in interest, taxes, inflation and exchange rates that layered down the established market growth in emerging the market for the power of the payers as decision makers. The change that could also affect the foreign currency can also affect the export and imports of the drugs. Patents in other countries pay a lot for the proportion of drug cots themselves that leads to...

Words: 1567 - Pages: 7

Global Pharmaceutical Industry

...balThe global pharmaceutical industry THE GLOBAL PHARMACEUTICAL INDUSTRY INTRODUCTION According to Hunter s. Thomas "you can turn your back on person, but never turn your back on a drug, especially when it's waving a razor sharp hunting." The global pharmaceutical industry had done tremendous contribution to mankind, but now pharmaceutical companies are facing tough time in a decade. The case is broken in to different parts which is emphasized on how internal and external factors affecting the industry firstly, the main environmental forces currently affecting the industry through PEST analysis. Secondly, the implications of the changes in business environment that is internal factors through porter's five force theory. Finally, the use and limitations of the tools applied to solve case are discussed. ORIGIN AND EVOLUTION The present pharmaceutical industries are non-assembled and more of competitive but it had emerged in early 19th century in the Rhine valley near Basel Switzerland where dyestuffs were found to have antiseptic properties. Companies like Hoffman-la rochy, Sandoz, Novartis are all started as Rhine based family dyestuff and chemical companies, which are still doing tremendous business even to day. Slowly these chemical companies started making pharmaceuticals and synthetic chemicals and evolved as global players. In early 1940's the industry showed drastic changes such as introduction of penicillin and other drugs. In 1960's industry growing rapidly......

Words: 2941 - Pages: 12

Ceo Compensation in the Pharmaceutical Industry

...for executives. In this paper, we are going to discuss the incentives of four different CEO from Pharmaceutical Industry. Pfizer Merck & Co Bristol-Myers Squibb Vertex 2012 Revenue $59B $47B $21B $1.5B 2011 Revenue $65B $48B $19B $1.0B CEO Read Frazier Andreotti Leiden Base $1.75M $1.5M $1.6M $1.0M Annual Incentive $3.4M $2.5M $3.8M $2.1M Annual LT Incentive (Stock and Stock Options) $12.9M $7.1M $10.9M $2.5M Perks/Other $175k $0.06M $808k $0.01M Vested/Exercised Shares $5.6M Approx. Total $25M $11.1M $17.2M $5.7M According to the Proxy statements, both Pfizer and Mereck have approximately 90% of their compensation as variable, based on company performance. The large discontinuity between the two companies is mostly due to the vested or exercised shares of Pfizer’s Ian Read. Excluding this amount, the companies’ compensation plans are generally aligned with their comparable sizes and company performance. Pfizer offered the largest incentive-based payout to it’s CEO in 2012, justified by the company exceeding two of three performance metrics despite key patent losses and the leadership Read showed throughout the year. Merck ranked their CEO performance as high in a tough environment, but due to a low internal scorecard results and shareholder return rankings Frazier was awarded a lower amount of variable compensation than in 2011. Overall, both of these industry leaders seem to have incentive programs aligned with company and shareholder......

Words: 1322 - Pages: 6

Industry Trends for the Pharmaceutical Industry

...Industry Trends According to Standard and Poor’s industry service, in the past few years, the pharmaceutical industry has been subjected to heightened competition from generic drugmakers, unprecedented pricing pressure from payers, and hard-to-control inflation in research and development budgets. Furthermore, the  industry has been experiencing a decline in R&D productivity, with a lack of innovative new products being launched in recent years. The industry has suffered due to these problems in 2010, however, improvements in early-stage product pipelines in certain fields, such as cancer and diabetes, show positive long-term potential. Major cost-cutting initiatives, including sales and marketing overhauls and the reorganization of R&D operations, have been introduced as a response to the industry's concerns. New products, as well as an aging population, also provide another indication that the industry has a promising future. 1. Emerging Markets Drive Growth With markets in major developed nations being stagnant or only showing modest growth, pharmaceutical manufacturers are focusing on global emerging markets to provide momentum for industry growth over the coming years. Projections show that these markets will account for over two-fifths of global GDP, and 80% of the world's population by 2015. With respect to the pharmaceutical industry, observers have forecast that emerging markets will drive up to 90% of the sector's growth through 2020. Based on IMS...

Words: 2026 - Pages: 9

Analysis of Indian Pharmaceutical Industry

...Chapter 2: Industry Analysis 9 * Industry Life Cycle * Porters 5 Forces * SWOT * PESTLE * Correlation 7) Chapter 3: Company Analysis 24 * Company Profiles (10 Companies) * Financial Ratio Analysis * DCF Valuation * Valuation Shares 8) Conclusion 74 9) Bibliography 76 RESEARCH OBJECTIVES Research Project Topic: “Analysis and Valuation of the Indian Pharma Sector” The research objectives of this specialization project are: 1) Identifying the key indicators of the Global Pharma Industry 2) Understand and analyze the Indian Pharma Industry and identify the prominent players. 3) To examine the trends in the pharma industry 4) Fundamental and Technical Analyses of the Top 10 pharma companies in India. The main objective of this study is: 1) Valuation of the Top 10 Pharma companies 2) Finding the correct share price of the company 3) Making investment decision of- Buying, Selling or Holding the stocks of the respective pharma company. EXECUTIVE SUMMARY * Global Pharma Industry is likely to grow at a CAGR of 5% to US $ 1 Trillion by 2013 * The Pharmaceuticals......

Words: 11741 - Pages: 47

Global Pharmaceutical Industry

...The primary focus of this essay is the analysis of the global pharmaceutical industry and the substantially significant factors that shape this industry; the industry is primarily defined by very few yet critically influential factors; these consist of: governing bodies, the role of corporate social responsibility, and the emphasis put on the industry and firms by the Research and Development process. The most consequential factor placing emphasis on the industry is the governing body, with it being the legislative body and largest purchaser of the industry exclusive of the USA creates a strategic dilemma for the corporations in terms of profit maximization. Patent limitation, regulatory controls, price or reimbursement controls and extensive safety legislations are methods adopted by the government to legislate control and limitations over the industry. These legislations construct a paradigm that the main objective behind the intervention is to keep medicinal costs low as the majority of the population i.e. under 18’s, over 65’s and people primarily on benefits, medical costs are paid for by the government and with the ageing population the expenditure is ever increasing hence the various limitations. Being the legislative body and the largest purchaser gives the government various types of buyer control; the case study implies that the industry is a “monopsony”, giving the corporations very little bargaining power in terms of profit maximization and can often alter the......

Words: 867 - Pages: 4

Pharmaceutical Industry

...threats for Pharmaceutical industry as these movements focus on green environments and reduce chemicals and carbon which comes from pharmaceutical industries. It is not being possible to ignore these issues as they are supposed to be practiced under United Nation charter for clean and better environment. For example Pfizer is a well reputed British Pharmaceutical company which has aims to save the environment as much as possible from chemicals, waste water which includes active pharmaceutical ingredients mixture of different compounds and carbon which comes from their pharmaceutical industries. Different strategies could be used to reduce carbon and chemical waste from drugs for human environment, like proper consumption ,good way of savages for hospitals waste water like advance waste water treatment technology, private house hold expire drugs, training and education of medical professionals to reduce over prescription, and public education and awareness. These strategies could be help full for save green house environment from drugs. In conclusion if we do focus on three principal strategies to reduce the input of chemicals compounds, carbon, and waste water in to the environment are substitution of complex chemical compounds, advance technical approach, and proper education and training of doctors, retailers and consumers. (Klaus Kümmerer, 2009) Social The social life, physical activities and level of health of a community affects the pharmaceutical industry. Change......

Words: 1468 - Pages: 6

Industry Analysis of the Pharmaceutical Industry

...Corporate Development Strategies Faculty 02 – Economics and Business Administration Johann Wolfgang Goethe-University Frankfurt Industry analysis of the pharmaceutical industry Written assignment Submitted by: Heiko Kreuz, 4897736, s5706079@stud.uni-frankfurt.de Janine Seelinger, 4896818, s1010710@stud.uni-frankfurt.de Dana Winkler, 4497800, s1099437@stud.uni-frankfurt.de Supervisor: Prof. Dr. Lars Schweizer November 6, 2015 Table of contents 1 Introduction...........................................................................................................................1 2 Theoretical framework of Porter’s Five Forces ........................................................1 3 Industry analysis by means of Porter’s Five Forces ................................................2 3.1 Competitive rivalry ................................................................................................... 2 3.2 Bargaining power of suppliers.................................................................................. 2 3.3 Bargaining power of buyers ..................................................................................... 2 3.4 Threat of substitutes ................................................................................................. 3 3.5 Threat of new entrants .............................................................................................. 3 3.6 The regulators ............................

Words: 1934 - Pages: 8

Pharmaceutical Industries

...INTERNSHIP REPORT ON TRAINING AND DEVELOPMENT PRACTICES OF INCEPTA PHARMACEUTICALS LTD. Submitted To: Mr. Shamim Ehsanul Haque Senior Lecturer BRAC Business School Submitted By: Nusrat Jahan Trisha ID – 09204115 BRAC Business School TABLE OF CONTENTS Title Page No Part- Ι Letter of Transmittals 5 Acknowledgement 6 Executive Summary 7 Part- ΙΙ Introductory Part 08-19 1.0 Introduction 09 1.1 Rationale of the Study 10 1.2 Objectives of the Study 11 2.0 Company overview 12-19 2.1 Profile of Incepta Pharmaceuticals Ltd. 12 2.2 History of IPL 12-13 2.3 Vision of IPL 13 2.4 Mission of IPL 13 2.5 Incepta Pharmaceuticals Ltd. at Glance 14 2.6 Divisions & Departments of IPL. 15 2.7 Organizational Hierarchy of IPL 16 2 2.8 Growth Rate of IPL 17 2.9 Products of IPL 18 2.10 CSR of IPL 19 ACTIVITIES UNDERTAKEN 20-37 3.1 Overview of HR practices in Incepta Pharmaceuticals Ltd. 21 3.1.1 Discussion about HRM 21 3.1.2 Functional area of HRM in Large Organization 21-22 3.1.3 Incepta Functional area of HRM 22-24 3.2 Overview of Training and Development Function of Incepta 25-44 3.2.1 Training Defined 25 3.2.2 Development 25 3.2.3 Importance of Training and Development 26 3.2.4 Review of Training function of Incepta 27 3.2.5 Types of training 28 3.2.6 Incepta Behaviors 29 3.2.7 Employee......

Words: 9658 - Pages: 39